Medico Remedies (NSE:MEDICO) EBIT: ₹199 Mil (TTM As of Mar. 2026)


NSE:MEDICO Medico Remedies Ltd NSE:MEDICO
86 GF Score
Price ₹40.28
GF Value ₹75.89
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medico Remedies EBIT?

Medico Remedies NSE:MEDICO -1.88% 86 EBIT is ₹199 Mil as of Mar. 2026. GuruFocus rates NSE:MEDICO with a GF Score™ of 86/100 and a GF Value™ of ₹75.89 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Medico Remedies's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹92 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹199 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medico Remedies's annualized ROC % for the quarter that ended in Mar. 2026 was 18.33%. Medico Remedies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 41.40%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medico Remedies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.67%.

Medico Remedies  (NSE:MEDICO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medico Remedies's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=253.968 * ( 1 - 29.6% )/( (0 + 975.64)/ 1 )
=178.793472/975.64
=18.33 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1534.033 - 520.829 - ( 37.564 - max(0, 776.426 - 1289.176+37.564))
=975.64

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Medico Remedies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=368.92/( ( (0 + max(0, 0)) + (229.491 + max(661.539, 0)) )/ 1 )
=368.92/( ( 0 + 891.03 )/ 1 )
=368.92/891.03
=41.40 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(819.924 + 300.158 + 128.705) - (520.829 + 0 + 66.419)
=661.539

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medico Remedies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=198.661/3502.052
=5.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medico Remedies EBIT Related Terms

Medico Remedies EBIT Historical Data

* Premium members only.

The historical data trend for Medico Remedies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medico Remedies EBIT Chart

Medico Remedies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.90 106.79 119.77 146.62 198.66

Medico Remedies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.93 27.15 37.09 42.19 92.23

NSE:MEDICO vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medico Remedies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medico Remedies EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medico Remedies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medico Remedies's EV-to-EBIT falls into.


NSE:MEDICO
86GF Score
Medico Remedies Ltd NSE:MEDICO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medico Remedies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹199 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹199 Mil mean?
Medico Remedies (NSE:MEDICO) has a EBIT of ₹199 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medico Remedies.
Is Medico Remedies' EBIT too high?
Medico Remedies' current EBIT is ₹199 Mil. Overall, Medico Remedies has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medico Remedies' EBIT compare to ZTS?
Medico Remedies' EBIT of ₹199 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medico Remedies. Medico Remedies's current EBIT is ₹199 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medico Remedies stock overvalued right now?
Based on GuruFocus' analysis, Medico Remedies (NSE:MEDICO) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹75.89, compared to a current price of ₹40.28 — trading 46.9% below its estimated fair value. The current EBIT is ₹199 Mil. Medico Remedies' overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Medico Remedies (NSE:MEDICO), the current EBIT is ₹199 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medico Remedies (NSE:MEDICO) Overvalued in 2026?

Based on GuruFocus' analysis, Medico Remedies stock appears to be undervalued. The current stock price of ₹40.28 is trading 46.9% below its estimated GF Value™ of ₹75.89. GuruFocus considers Medico Remedies to be Significantly Undervalued.

Key valuation signals for NSE:MEDICO:

  • EBIT: ₹199 Mil
  • GF Value™: ₹75.89 vs. price of ₹40.28 (46.9% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the NSE:MEDICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medico Remedies Business Description

Other Exchanges 540937:India
Address N. S. Phadke Marg, Opposite Teligali, 1105/1106, 11th Floor, Hubtown Solaris, Andheri (East), Mumbai, MH, IND, 400069
Medico Remedies Ltd is a manufacturer, supplier, and exporter of pharmaceutical drugs. It operates in single segment single segment of manufacturing medicines including Antihy pertensive Antidiabetics Antibictics Diuretics, Antimalarials, NSAIDS Tablets, Antireterovirals, Anti-Ulcer Drugs and Antacids Tablets, so many drugs used for treatment of so many diseases for oral use as well as external preparations like creams & ointments which includes anti infectives ,antifungals ,antibiotics ,steroidal preparations etc. In addition, it also sells other drugs such as antihistaminic, antidiabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments.
86GF Score

Get the complete analysis for NSE:MEDICO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹40.28
Price
₹75.89
GF Value